Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor, Ruxolitinib, and Methylprednisolone in Relapsed/Refractory Multiple Myeloma
NCT06225310Phase 1Recruiting
- Sponsor
- ONCOtherapeutics
- Start
- Aug 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor and ruxolitinib in multiple myeloma (MM), sponsored by ONCOtherapeutics. Primary endpoints: Maximum Tolerated Dose at 30 months and Recommended Phase 2 Dose at 30 months. Started Aug 2024; status: recruiting.
02
Drugs
selinexorruxolitinib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06225310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06225310.